Latest news with #Compumedics
The Australian
05-08-2025
- Business
- The Australian
Compumedics wins sales as broker lifts target ~140pc
Compumedics secures two lucrative sales for its Somfit sleep device with combined revenues approaching $2 million Sales to a leading CRO in US and a Finnish pharmaceutical company support strategy to expand in adjacent markets East Coast Research revises Compumedics target price to 75 cents per share, showing upside potential of 138.7% Special Report: Compumedics has secured lucrative multiple Somfit sales to leading pharmaceutical and clinical research organisations (CROs) in the US and Europe East Coast Research sees an almost 140% upside to its current target price. Compumedics (ASX: CMP), a global medical device company specialising in sleep, brain and ultrasonic blood flow monitoring, has inked a sale with a leading CRO for its Somfit devices. The company noted the devices will be used in a major US-based clinical drug trial with one of the world's largest pharmaceutical companies. Compumedics also secured a second sale with Finland-based global pharmaceutical firm Orion Pharma for deployment of Somfit devices across a multi-country, multi-centre clinical study in Europe. Somfit is a wearable device used for collecting physiological data during sleep with combined revenues from both sales approaching $2 million. The sales support the company's strategy to expand into adjacent markets, where Somfit's ability to collect electroencephalography (EEG) signals and provide insights into sleep stages and patterns provides a distinct advantage over traditional home sleep testing systems. The contracts also validate Somfit's clinical value proposition in the pharmaceutical sector, where understanding the effects of new drugs on sleep is becoming an increasingly important regulatory and research requirement. 'Building a diversified global business' Executive chairman and CEO Dr David Burton said the sales wins highlight the growing momentum Compumedics was seeing for Somfit in new market segments. 'The pharmaceutical clinical trial market is an ideal adjacency for our technology, and these early contracts, approaching $2 million in combined value, demonstrate Somfit's versatility beyond traditional home sleep testing,' 'This is another important step in building a diversified global business with multiple high growth pathways." Compumedics expects to build on this early traction, continuing engagement with major pharmaceutical companies and research institutions worldwide. Broker re-rates Compumedics following milestones and global expansion Meanwhile, East Coast Research has revised its target price for Compumedics to 75 cents per share, representing an upside potential of 138.7% from the share price at the time of its review and an 11.9% increase on its previous 67 cent target set in March. In its updated valuation, East Coast Research set a base case of 59 cents per share and an upside case of 92 cents, with a price-to-NAV (net asset value) of 0.42x. The Sydney-based equity research house said the re-rating reflected several key achievements, including: Record FY25 sales orders of $63.4m, up 22% YoY and return to profitability with $3m EBITDA for the financial year Validation of its world-first dual-use Orion LifeSpan MEG system Strong FY26 guidance with $70m in revenue and $9m in EBITDA supported by US launch of Somfit D, rising SaaS contributions and delivery of three MEG systems A $24.4 million pipeline secured through two long-term distribution agreements in China Broader entry into pharmaceutical trials 'These developments not only strengthen CMP's position in high-growth segments like SaaS and brain imaging but also significantly de-risk its revenue outlook and enhance its value proposition in the global medtech and connected health markets,' the broker noted. East Coast said Compumedics remained well-positioned for long-term value creation. This article was developed in collaboration with Compumedics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
The Australian
28-07-2025
- Business
- The Australian
Compumedics signs lucrative China deals
Compumedics signs two lucrative four-year distribution deals in Asia strengthening footprint in region An agreement worth $20 million signed with sleep diagnostics distributor in Northern China Second agreement, worth $4.4 million, inked with sleep and neurological distributor in Eastern China Special Report: Compumedics, a global medical device company specialising in sleep, brain and ultrasonic blood flow monitoring, has signed two new four-year distribution agreements with long-standing partners in China worth a combined $24.4 million. These deals further strengthen Compumedics' (ASX:CMP) footprint in Asia, and China in particular, where the company has a long history and current distribution partners of more than 25 years. The first $20m agreement extends Compumedics' established partnership with its long-term Northern China distributor focused on sleep diagnostics. The second, valued at $4.4m, renews a long-standing relationship with an Eastern China distributor focused on sleep and neurology. Both agreements include a minimum of 10% per annum growth commitment, providing a clear trajectory for expanding sales in one of Compumedics' most strategically important markets. The agreements reflect the company's continued strategic shift toward a more diversified and resilient revenue base, both geographically and across product lines. Strengthening key relationships in Asia, particularly in China, aims to reinforce Compumedics' ability to drive consistent growth through its core sleep and neurology platforms. With a solid foundation in place and demand accelerating across multiple international markets, the company is working to remain well positioned to scale efficiently and deliver sustained, profitable growth into FY26 and beyond. Return to profitability in FY25 Compumedics recently reported record revenue of $51m and sales orders of $63.4m in FY25 and a return to profitability with EBITDA increasing to ~$3m. Its sleep and neurology segment orders rose 39% to $53m in FY25, led by US sleep diagnostics growth up 102% to $23.5m. Its Neuroscan Orion LifeSpan magnetoencephalography (MEG) orders totalled $5.9m, with three systems in progress for reported revenue in FY26 valued at ~$15m. MEG is an advanced brain imaging technique that maps neural activity by detecting the tiny magnetic fields produced by electrical currents in the brain. Compumedics' Neuroscan Orion LifeSpan MEG system offers enhanced precision and full integration with its CURRY software, which records and analyses EEG, MEG and ERP for comprehensive brain function insights. The company has reaffirmed its FY26 guidance of revenue of at least $70m and EBITDA of ~$9m. 'China remains key engine for expansion' Compumedics is establishing itself as the dominant supplier of MEG technology in the growing Chinese neurosciences market. In March the company received a new order from Hangzhou Normal University (HZNU) in China for its MEG system valued at $5.7m, which is scheduled to ship in early 2026 following site preparations. That order brings installations to four Compumedics MEG labs in China for a total of ~$20m in revenues. Executive chairman and CEO Dr David Burton said the new agreements highlighted Compumedics' strategic momentum and supported its long-term growth plans. 'These agreements demonstrate the strong momentum behind the step-change underway at Compumedics, a shift focused on profitable growth, recurring revenue and geographic diversification,' he said. 'China remains a key engine for expansion and these multi-year contracts secure predictable, growing revenues in one of our most strategically important markets. 'Coupled with increasing traction in the US and across our connected platforms, we are now scaling a more focused, cash-generative global business.' This article was developed in collaboration with Compumedics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
News.com.au
14-07-2025
- Business
- News.com.au
Health Check: Imugene goes to the well after reporting more blood cancer ‘cures'
Imugene reports two more 'complete responders' in its cell therapy trial Clever Culture Systems shares surge 17% on deal with Big Pharma Novo Nordisk Compumedics shares vault 24% after full-year update Imugene (ASX:IMU) will forge ahead with a planned pivotal US trial for its blood cancer therapy Azer-cel, having recorded more 'complete responses' in its phase 1b study. There's also the matter of cash, with Imugene shares this morning entering trading halt amidst a capital raising reportedly targeting $35 million. The trial is testing the company's CD-19 Car-T therapy on patients with relapsed diffuse large B-cell lymphoma. This is an especially aggressive blood cancer and these patients have failed multiple therapies. The company reports that of five further patients evaluated, two showed a 'complete response'. A complete response is the disappearance of all cancer signs – a.k.a. a cure. A further five showed a 'partial response' – at least a 50% cancer cell reduction. This takes the total number of complete responses to six and partial responses to three, out of 12 patients. The effect has endured for at least 60 days, with the first patient treated remaining cancer free at the 15-month mark. 'Allo 'allo, we're on to something If approved, Azer-cel would be the first off-the-shelf Car-T therapy using donor cells rather than the patients' own material. This is the allogeneic (allo), as opposed to autologous, method. Car-T therapies involve taking T-cells out of blood and tricking them up with agents that bolster their cancer-busting abilities. They are then re-introduced into the bloodstream. The re-engineered cells pursue a target, in this case the CD-19 protein expressed by blood cancers. Next stop: FDA The ongoing study is being carried out at 13 US sites and the first of five planned local sites. The company in February treated the first Australian participant, at Sydney's Royal Prince Alfred Hospital. The subjects were dosed with Azercel, combined alongside chemotherapy and the immunity agent interleukin 2. Imugene plans to meet with the US Food & Drug Administration (FDA) in the December quarter, to discuss a pivotal registration study. As of the end of March, Imugene held cash of $36 million. Drug development is hideously expensive and the last raising is never the final one, and what better time to go to the well than after positive clinical results? Imugene raised $53 million in 2023 and $80 million in 2020 and this year entered into a $20 million convertible note issue. Imugene shares have lost 68% year to date, adjusting for a share consolidation that reduced its 7.46 billion shares on issue to a more respectable 219 million. Clever Culture bulks up with fat-busting drug maker Clever Culture Systems (ASX:CC5) has signed up Big Pharma Novo Nordisk for one of its automated agar plate reading devices to monitor ultra-clean drug making facilities. The maker of the weight loss and diabetes drugs Ozempic and Wegovy, Novo Nordisk will acquire and appraise one of Clever Culture's AI-enabled device APAS Independence units, in view of a full global rollout across its facilities. The AI-enabled APAS Independence devices automatically read the hundreds of agar plates required to ensure that pathogens don't enter aseptic facilities. The units can manage 200 plates per hour, freeing up microbiologists to focus on the minority of plates that read positive. To date Clever Culture has focused on 90 millimetre 'settle' plates that are left open, to absorb any nasties in the room. A tweaked APAS also will read 55mm 'contact' plates, which are dabbed on surfaces, such as a gown or gloved fingertips. Nova Nordisk will assess both settle and contact plate modules. Courting Big Pharma Clever Culture CEO Brent Barnes says the 'milestone' deal aligns with the company's focus on the big drug makers, most of which have centres to appraise new products. To date Clever Culture also sold the devices to Astrazeneca, Bristol Myers Squibb and Thermo Fisher Pharma Services, while a fifth drug maker recently completed a 'successful evaluation'. The five drug makers on the books represent a sales opportunity of between 60 to 80 units. At last count the company had 13 APAS devices in the field, with foundation client Astrazeneca accounting for nine of them. The company cites a 'pipeline' of 40 customers, representing upfront revenue of about $75 million and $15 million of recurring revenue. The APAS unit sells for US$350,000, but Clever Culture then derives ongoing income from an annual software licence of US$30,000 (rising to US$50,000 with the contact plate modality). There's also an annual hardware maintenance fee of $US15,000-25,000. The FDA approved APAS Independence in May 2019 and European regulators followed suit in September 2021. There's no snoozing at Compumedics Sleep and neurological testing house Compumedics (ASX:CMP) has reported record revenue of $51 million for the year to June 2025, up 4%. What's more, the company has returned to profitability, with underlying earnings of $3 million. Compumedics also reports record sales orders of $63.4 million, up 22%. The key driving force was the growth of the US sleep diagnostics arm, up 39% to $53 million. The company also affirmed current year guidance of revenue of at least $70 million and underlying earnings of around $9 million. 'This result reflects the step-change underway at Compumedics,' founder and executive chairman Dr David Burton says. "We are building a more predictable, higher-margin business model and seeing consistent revenue growth, expanding margins and meaningful traction in the US." Proteomics ain't horsing around In time for the spring racing season, Proteomics International Laboratories (ASX:PIQ) says its oxidative stress test Oxidx can detect muscle damage in thoroughbreds. As published in the peer-reviewed journal Veterinary Medicine and Science, the 'groundbreaking' results show Oxidx can identify and assess recovery from exercise-induced damage. The study was based on 34 nags. The company says up to 85% of thoroughbreds sustain at least one injury during their racing seasons, potentially because of undetected muscle injuries. 'Oxidative stress has been implicated in many disease and injury states, with levels often reflective of a person or animal's health condition.' Via its 66% owned OxiDx Pty Ltd, Proteomics plans to launch Oxidx locally in the current half. Proteomics has a commercialised diabetic kidney disease diagnosis and plans to launch an endometriosis assay locally in the current quarter. No pay, no worries says Pacific Edge Pacific Edge (ASX:PEB) reports resilient demand for its bladder cancer diagnostic in the US, despite authorities withdrawing reimbursement coverage. The Kiwi-based company said US June quarter test volumes declined 12% to 5717, relative to the March quarter. Asia Pacific volumes – including those derived here – rose 8.8% to 1183. The company attributed the decline mainly to customers moving to its Cxbladder Triage product, from the discontinued Cxbladder Detect. Cxbladder Triage tests accounted for 77% of total US assays, up from 22% in the March quarter. Pacific Edge also said it had held positive discussions with Novitas, its US Medicare gatekeeper, about reinstating coverage. This was 'based on evidence not considered in the review that led to the non-coverage decision.'
News.com.au
02-07-2025
- Health
- News.com.au
Compumedics' dual-helmet brain tech hits a nerve in China's neuroscience boom
China Brain Project rolls out neuro-AI push Compumedics dual-helmet MEG lights up Tianjin labs ASX health stocks surge deeper into China A few years back, China kicked off what might be one of the most ambitious science missions you've never heard of: the China Brain Project. This is a full-scale national effort to figure out how the brain works, fix what goes wrong when it doesn't, and use all that insight to build the next generation of artificial intelligence. Launched in September 2021, the project strings together 59 headline studies, backed by about RMB 3.2 billion ($680 million) under a framework cheerfully called 'one body, two wings.' The 'body' focuses on fundamental neuroscience, how we learn, think, feel and remember. One 'wing' tackles brain disorders like epilepsy, autism and dementia, aiming to improve diagnosis and treatment. The other 'wing' is all about brain-inspired tech: building machines that mimic how humans learn and adapt, rather than just crunching data the old-fashioned way. But to get from elegant theory to real-world breakthroughs, scientists need to see the brain in action. Not just its structure, but its split-second activity as thoughts, memories and decisions light up the neurons. That's where brain imaging comes in. MRI gives you high-res still shots of the brain's anatomy – useful, but static. MEG, or magnetoencephalography, is the opposite: it captures the brain in motion, recording real-time electrical activity down to the millisecond. MEG listens to the brain's own magnetic murmurs, but legacy systems come with two big drawbacks. One-size-fits-adults helmets leave a child's head rattling around like a pea in a tin, so the sensors sit too far from the brain and the signal fizzles. Even worse, most MEG systems burn through liquid helium to keep the sensors cold. And when that coolant runs low, the whole scanner has to shut down until a refill arrives, usually in the form of a specialised delivery, which isn't always quick or easy. China's new brain labs wanted something nimbler. Enter an Australian outsider. Compumedics lands world-first dual-helmet MEG Compumedics (ASX:CMP), a med-tech company based in Melbourne, spent nearly ten years developing a new kind of MEG system with its research partners at Korea's KRISS institute. The result is the Orion LifeSpan, a scanner that holds two helmets, one for adults and one for children, inside a single cooling chamber (called a dewar). It uses advanced, patented sensors known as DROS-SQUIDs to pick up the brain's magnetic signals with high precision. Unlike older systems that need constant helium refills, Orion recycles almost all its coolant, so it can keep running around the clock without shutting down. It also has a 'hyperscanning' mode, which can record the brain activity of two people at the same time. That's useful, for example, if you're studying how a child's brain interacts with their parent's during a shared task. Tianjin Normal University (TJNU) secured the first Orion in late 2024. After months of tests, the university gave formal acceptance and called it the most advanced MEG lab on the planet. 'The Orion LifeSpan MEG recently installed by Compumedics at TJNU has been a revolution in our ability to study mental processes of both children and adults, or even the two simultaneously," said Vice-President Professor Xuejun Bai. 'The system has already proven itself to be extremely sensitive, accurate and reliable.' TJNU researchers sat a four-year-old under the Orion LifeSpan MEG and fed 200 quick tones into one ear, while the scanner captured her brain's magnetic response. With the paediatric helmet snug to her scalp, the auditory peaks popped up about 90 milliseconds after each beep – clear, high-amplitude waveforms that lit the display like a studio-grade equaliser. Then the team simply rotated Orion's dual-helmet dewar to bring the adult dome into place, and ran the exact same test. This time the signals barely rose above the noise floor; the larger helmet kept the sensors centimetres farther from her brain, and most of the field strength bled away before it reached the coils. That side by side comparison, all on a single machine, delivered what Compumedics later called 'the first time a single MEG system had given high-quality scans for both children and adults.' Compumedics has proven that shortening the brain-to-sensor gap and boosting the signal-to-noise ratio can unlock the precision that paediatric neurology has long been waiting for. China's brain labs line up The TJNU showcase set off a modest domino run. Tsinghua University signed on, a second Tianjin facility followed, and Hangzhou Normal University ordered its own Orion LifeSpan package. The four contracts total roughly $20 million, with Hangzhou's unit slated for delivery in early 2026. Compumedics isn't claiming to own the market; it's simply first out of the blocks. MEG scanners are still rare in China compared with the country's vast MRI fleet, and Orion's dual-helmet design halves both the hardware bill and the room it needs, exactly the kind of maths provincial governments like as they race to build new neuroscience centres. None of it turns Compumedics into a household name overnight, but it does explain why four Chinese universities have already signed purchase orders. And as the China Brain Project accelerates, the real-time windows provided by MEG are likely to move from niche to mainstream. China becomes launchpad for ASX health plays With its sheer scale, ageing population and a government rolling out the red carpet for cutting-edge medical tech, China has become a proving ground that's increasingly hard for ASX health outfits to ignore. Compumedics isn't the only Aussie med-tech with serious skin in the China game. Telix Pharmaceuticals (ASX:TLX), for instance, is running several China-based Phase III registration studies. The ZIRCON-CP trial of its kidney-cancer imaging agent TLX250-CDx is being conducted at Beijing Cancer Hospital and other leading oncology centres, in conjunction with strategic partner Grand Pharmaceutical Group. The first Chinese patient was dosed late-2024, and the study remains active in 2025. Cochlear (ASX:COH) continues its three-decade clinical presence in China. In June, the company launched its Nucleus Nexa smart implant within the Boao Lecheng International Medical Tourism Pilot Zone, a government-sanctioned hospital hub that fast-tracks novel devices and collects clinical evidence for mainland approval. EZZ Life Science (ASX:EZZ), meanwhile, has quietly pulled off one of the sharpest China plays on the ASX, turning a niche Aussie wellness brand into a breakout star. In FY24, revenue surged 79% to $66.4 million, with a clean $10.4 million in EBITDA and zero debt on the books. And 80% of that cash came straight out of Greater China, thanks to a killer e-commerce strategy across Douyin, Tmall, Kuaishou and O'Mall, where its anti-ageing pills and children growth chews have become chart-toppers. Parents in China can't get enough of EZZ's kids' range, and the company just dropped a fresh $21 million deal to push into Thailand, Vietnam and Singapore. At Stockhead we tell it like it is. While Compumedics and EZZ Life Science are Stockhead advertisers, they did not sponsor this article.
Herald Sun
04-06-2025
- Business
- Herald Sun
Vital Signs: Compumedics
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to Gordon Haid, the Global Neuro-Imaging Business Director of Compumedics (ASX:CMP), a medical device company focused on diagnostic tech for sleep, brain and blood flow monitoring. Founded in 1987, Compumedics' strategy was initially focused on developing its core competency, Sleep Diagnostics. The company even set up Australia's first ever fully computerised sleep clinic. Today, Compumedics has evolved into one of the world's leading suppliers of medical technology for sleep, neuro diagnostics and ultrasonic blood flow monitoring, with products distributed to clients around the globe, helping millions of people who suffer from debilitating sleep, neurological and other healthcare problems. This podcast was developed in collaboration with Compumedics, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions. Originally published as Vital Signs Podcast: Breakthrough brain scanning technology overcoming diagnostic hurdles
